# EDGAR Filing Document

**Accession Number:** 0001974915
**File Stem:** 0001974915-25-000007
**Filing Date:** 2025-8
**Character Count:** 31423
**Document Hash:** 7d78fbe438cfee8eb4833b85a7ff39c8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001974915-25-000007.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001974915-25-000007

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vestal Point Capital, LP
- **CENTRAL INDEX KEY:** 0001974915

**ORGANIZATION NAME:**
- **EIN:** 922296021
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-23784
- **FILM NUMBER:** 251261769

**BUSINESS ADDRESS:**
- **STREET 1:** 632 BROADWAY
- **STREET 2:** SUITE 602
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10012
- **BUSINESS PHONE:** 6469894000

**MAIL ADDRESS:**
- **STREET 1:** 632 BROADWAY
- **STREET 2:** SUITE 602
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10012

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001974915

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Vestal Point Capital, LP

**Address:** 632 Broadway, New York, NY 10012

**Telephone number:** 646-989-4000

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-23784

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 5493000BKRWNKB4XNM02

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                             | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                         | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Jazz Pharmaceuticals plc                   | G50871105 | 07/25/2024     | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement.                                                                               | SECTION 14A SAY-ON-PAY VOTES |      1.33972e+06 |                0 | FOR         |                              1.33972e+06 | FOR                         |  |
| Jazz Pharmaceuticals plc                   | G50871105 | 07/25/2024     | To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.                                                                   | SECTION 14A SAY-ON-PAY VOTES |      1.33972e+06 |                0 | ONE YEAR    |                              1.33972e+06 | FOR                         |  |
| KalVista Pharmaceuticals, Inc.             | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      1.5954e+06  |                0 | FOR         |                              1.5954e+06  | FOR                         |  |
| Zymeworks Inc.                             | 98985Y108 | 12/10/2024     | Advisory Vote on the compensation of our named executive officers                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 545995           |                0 | FOR         |                         545995           | FOR                         |  |
| Hologic Inc.                               | 436440101 | 02/26/2025     | A non-binding advisory vote to approve executive compensation.                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  41203           |                0 | FOR         |                          41203           | FOR                         |  |
| Verona Pharma Plc                          | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 306254           |                0 | AGAINST     |                         306254           | AGAINST                     |  |
| Abbott Laboratories                        | 002824100 | 04/25/2025     | Say on Pay - An Advisory Vote on the Approval of Executive Compensation                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |   1507           |                0 | FOR         |                           1507           | FOR                         |  |
| Perrigo Company plc                        | G97822103 | 05/01/2025     | To provide advisory approval of the Company's executive compensation                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 919186           |                0 | FOR         |                         919186           | FOR                         |  |
| Bristol-Myers Squibb Company               | 110122108 | 05/06/2025     | Advisory Vote to Approve the Compensation of our Named Executive Officers                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |  73902           |                0 | FOR         |                          73902           | FOR                         |  |
| Danaher Corporation                        | 235851102 | 05/06/2025     | To approve on an advisory basis the Company's named executive officer compensation.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  91471           |                0 | FOR         |                          91471           | FOR                         |  |
| Cytokinetics, Incorporated                 | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.32935e+06 |                0 | FOR         |                              1.32935e+06 | FOR                         |  |
| Vera Therapeutics, Inc.                    | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      1.68001e+06 |                0 | FOR         |                              1.68001e+06 | FOR                         |  |
| Vera Therapeutics, Inc.                    | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      1.68001e+06 |                0 | ONE YEAR    |                              1.68001e+06 | FOR                         |  |
| Insmed Incorporated                        | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 493735           |                0 | FOR         |                         493735           | FOR                         |  |
| Nurix Therapeutics, Inc.                   | 67080M103 | 05/19/2025     | To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 321899           |                0 | FOR         |                         321899           | FOR                         |  |
| Geron Corporation                          | 374163103 | 05/21/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      1.85049e+07 |                0 | FOR         |                              1.85049e+07 | FOR                         |  |
| MacroGenics, Inc.                          | 556099109 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials.                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 235200           |                0 | FOR         |                         235200           | FOR                         |  |
| Dianthus Therapeutics, Inc.                | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 769639           |                0 | AGAINST     |                         769639           | AGAINST                     |  |
| SCHOLAR ROCK HOLDING CORPORATION           | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 420545           |                0 | FOR         |                         420545           | FOR                         |  |
| Establishment Labs Holdings Inc.           | G31249108 | 05/23/2025     | To approve, on an advisory basis, the compensation of our named executive officers;                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 184401           |                0 | FOR         |                         184401           | FOR                         |  |
| Arcellx, Inc.                              | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                     | SECTION 14A SAY-ON-PAY VOTES |      2.01833e+06 |                0 | FOR         |                              2.01833e+06 | FOR                         |  |
| GE Healthcare Technologies, Inc.           | 36266G107 | 05/28/2025     | Approval of our named executive officers' compensation in an advisory vote.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 157814           |                0 | FOR         |                         157814           | FOR                         |  |
| Bruker Corporation                         | 116794108 | 05/29/2025     | Approval on an advisory basis of the 2024 compensation of our named executive officers, as discussed in the Proxy Statement.                                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 252001           |                0 | FOR         |                         252001           | FOR                         |  |
| Fate Therapeutics, Inc.                    | 31189P102 | 05/29/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      1.05666e+06 |                0 | FOR         |                              1.05666e+06 | FOR                         |  |
| Fate Therapeutics, Inc.                    | 31189P102 | 05/29/2025     | To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                     | SECTION 14A SAY-ON-PAY VOTES |      1.05666e+06 |                0 | ONE YEAR    |                              1.05666e+06 | FOR                         |  |
| Dyne Therapeutics, Inc.                    | 26818M108 | 05/30/2025     | To vote, on an advisory basis, to approve the compensation of our named executive officers.                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      1.18394e+06 |                0 | FOR         |                              1.18394e+06 | FOR                         |  |
| Dyne Therapeutics, Inc.                    | 26818M108 | 05/30/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      1.18394e+06 |                0 | ONE YEAR    |                              1.18394e+06 | FOR                         |  |
| Day One Biopharmaceuticals, Inc.           | 23954D109 | 06/02/2025     | Approval, on a non-binding advisory basis, of the compensation of our named executive officers.                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      1.73675e+06 |                0 | FOR         |                              1.73675e+06 | FOR                         |  |
| Kiniksa Pharmaceuticals International, plc | G52694109 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 140613           |                0 | FOR         |                         140613           | FOR                         |  |
| Voyager Therapeutics, Inc.                 | 92915B106 | 06/03/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 925991           |                0 | FOR         |                         925991           | FOR                         |  |
| Cogent Biosciences, Inc.                   | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      1.94393e+06 |                0 | FOR         |                              1.94393e+06 | FOR                         |  |
| Globus Medical, Inc.                       | 379577208 | 06/04/2025     | To approve, in an advisory vote, the compensation of the Company's named executive officers (the Say-on-Pay Vote).                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES | 215710           |                0 | FOR         |                         215710           | FOR                         |  |
| Globus Medical, Inc.                       | 379577208 | 06/04/2025     | To approve, in an advisory vote, the frequency of the approval, on an advisory basis, of the compensation of our named executive officers (the Frequency Vote).                                                                          | SECTION 14A SAY-ON-PAY VOTES | 215710           |                0 | ONE YEAR    |                         215710           | FOR                         |  |
| Ventyx Biosciences, Inc.                   | 92332V107 | 06/04/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote").             | SECTION 14A SAY-ON-PAY VOTES |      1.68e+06    |                0 | AGAINST     |                              1.68e+06    | AGAINST                     |  |
| Xenon Pharmaceuticals Inc.                 | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers;                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.12565e+06 |                0 | FOR         |                              1.12565e+06 | FOR                         |  |
| Amicus Therapeutics, Inc.                  | 03152W109 | 06/05/2025     | Approval, on an advisory basis, the Company's executive compensation.                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      4.03474e+06 |                0 | FOR         |                              4.03474e+06 | FOR                         |  |
| Celldex Therapeutics, Inc.                 | 15117B202 | 06/05/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.                                                                                                       | SECTION 14A SAY-ON-PAY VOTES | 157946           |                0 | FOR         |                         157946           | FOR                         |  |
| MoonLake Immunotherapeutics                | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 175322           |                0 | FOR         |                         175322           | FOR                         |  |
| Sarepta Therapeutics, Inc.                 | 803607100 | 06/05/2025     | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 194404           |                0 | FOR         |                         194404           | FOR                         |  |
| Savara Inc.                                | 805111101 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executives.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      6.95057e+06 |                0 | FOR         |                              6.95057e+06 | FOR                         |  |
| Savara Inc.                                | 805111101 | 06/05/2025     | To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executives.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      6.95057e+06 |                0 | ONE YEAR    |                              6.95057e+06 | FOR                         |  |
| Arcturus Therapeutics Holdings Inc.        | 03969T109 | 06/06/2025     | Approval, by non-binding advisory vote, of the resolution approving the Company's Named Executive Officer compensation, as provided in Proposal Number 2 of the Proxy Statement.                                                         | SECTION 14A SAY-ON-PAY VOTES | 273467           |                0 | FOR         |                         273467           | FOR                         |  |
| Sutro Biopharma, Inc.                      | 869367102 | 06/06/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      1.68525e+06 |                0 | FOR         |                              1.68525e+06 | FOR                         |  |
| Applied Therapeutics, Inc.                 | 03828A101 | 06/09/2025     | To approve (on a non-binding advisory basis) the compensation of our named executive officers as described in the accompanying materials.                                                                                                | SECTION 14A SAY-ON-PAY VOTES |      8.72594e+06 |                0 | FOR         |                              8.72594e+06 | FOR                         |  |
| Applied Therapeutics, Inc.                 | 03828A101 | 06/09/2025     | To approve (on a non-binding advisory basis) the frequency of an advisory vote on the compensation of our named executive officers in future years.                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      8.72594e+06 |                0 | ONE YEAR    |                              8.72594e+06 | FOR                         |  |
| Atara Biotherapeutics, Inc.                | 046513206 | 06/10/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  59434           |                0 | FOR         |                          59434           | FOR                         |  |
| Atara Biotherapeutics, Inc.                | 046513206 | 06/10/2025     | To approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers.                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |  59434           |                0 | ONE YEAR    |                          59434           | FOR                         |  |
| Alector, Inc.                              | 014442107 | 06/11/2025     | Advisory vote on executive compensation.                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 616898           |                0 | FOR         |                         616898           | FOR                         |  |
| Astria Therapeutics, Inc.                  | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      3.11518e+06 |                0 | AGAINST     |                              3.11518e+06 | AGAINST                     |  |
| Crinetics Pharmaceuticals, Inc.            | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; | SECTION 14A SAY-ON-PAY VOTES | 951565           |                0 | FOR         |                         951565           | FOR                         |  |
| Tenax Therapeutics, Inc.                   | 88032L605 | 06/11/2025     | Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  53439           |                0 | FOR         |                          53439           | FOR                         |  |
| Tenax Therapeutics, Inc.                   | 88032L605 | 06/11/2025     | Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  53439           |                0 | ONE YEAR    |                          53439           | AGAINST                     |  |
| uniQure N.V.                               | N90064101 | 06/11/2025     | Approval, on an advisory basis, of the compensation of the named executive officers of the Company.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.53828e+06 |                0 | FOR         |                              1.53828e+06 | FOR                         |  |
| Solid Biosciences Inc.                     | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      1.18823e+06 |                0 | AGAINST     |                              1.18823e+06 | AGAINST                     |  |
| Liquidia Corporation                       | 53635D202 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 819272           |                0 | FOR         |                         819272           | FOR                         |  |
| Cidara Therapeutics, Inc.                  | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 379546           |                0 | AGAINST     |                         379546           | AGAINST                     |  |
| Nuvalent, Inc.                             | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 972068           |                0 | AGAINST     |                         972068           | AGAINST                     |  |
| Protagonist Therapeutics, Inc.             | 74366E102 | 06/20/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |  10731           |                0 | FOR         |                          10731           | FOR                         |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                       | SECTION 14A SAY-ON-PAY VOTES | 881502           |                0 | FOR         |                         881502           | FOR                         |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 881502           |                0 | ONE YEAR    |                         881502           | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Vestal Point Capital, LP

**By (Signature):** Ilko Menkov

**By (Printed Signature):** Ilko Menkov

**By (Title):** Partner, COO and CCO

**Date:** 08/27/2025